There are currently 13 active clinical trials seeking participants for Hepatic Impairment research studies. The states with the highest number of trials for Hepatic Impairment participants are Florida, Texas, California and Tennessee.
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Recruiting
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/01/2024
Locations: Inland Empire Clinical Trials, Rialto, California +4 locations
Conditions: Hepatic Impairment, Cirrhosis